The biotechnology and biopharmaceutical landscape features several major companies dedicated entirely or significantly to oncology research, drug discovery, and commercialized cancer therapies. Prominent global leaders include firms like Amgen, Seattle Genetics (acquired by Pfizer), Regeneron Pharmaceuticals, Genentech (part of Roche), BeiGene, AstraZeneca, and specialized clinical-stage innovators such as Blueprint Medicines and IDEAYA Biosciences. These enterprises focus heavily on developing targeted small molecules, monoclonal antibodies, antibody-drug conjugates (ADCs), and cell-based immunotherapies designed to treat diverse solid tumors and hematological malignancies more effectively.